Varda returns the first commercial space-drug cargo to Earth, raises $329M

Designing, building and operating autonomous spacecraft that manufacture pharmaceutical products in microgravity and return them to Earth in reentry capsules.

That drug crystals form better in microgravity, making in-orbit pharmaceutical manufacturing a real market worth a dedicated factory and reentry capsule service.

$90M Series B led by Caffeinated Capital (April 2024); $187M Series C (July 2025) brought total raised to about $329M

Founded in January 2021 by Will Bruey and Delian Asparouhov, Varda bet that cheaper launch would make low Earth orbit a manufacturing location. It ordered custom spacecraft from Rocket Lab and chose drug crystallization as its first commercial wedge.

W-1 launched in mid-2023 and grew crystals of ritonavir, an HIV antiviral, in a 27-hour experiment. The capsule waited months after the FAA denied an early reentry request, but landed at the Utah Test and Training Range on Feb 21, 2024 — the first commercial spacecraft to land on U.S. soil and the first space-manufacturing mission outside the ISS. A $90M Series B followed in April 2024. W-2 launched Jan 14, 2025 and landed in South Australia on Feb 28, the first commercial spacecraft to touch down in Australia.

A $187M Series C in July 2025 brought total capital to about $329M, funding new pharmaceutical labs in El Segundo and an office in Huntsville, Alabama. By mid-2025 the company said it had completed three launch-and-return missions, with a fourth vehicle (W-4) in orbit under the FAA's first-ever reentry vehicle operator license. The manufacture-and-return loop is proven, though drug revenue is still pre-commercial.

ISS research had already shown microgravity improves drug crystals, so the unmet need was a return vehicle, not basic science.

Buying Rocket Lab spacecraft let Varda skip building a satellite from scratch and concentrate on reentry and the manufacturing payload.

Each successful return — Utah in 2024, Australia in 2025 — built the regulatory and operational track record pharma partners require.

Government hypersonic-test payloads paid for early flights while pharmaceutical revenue was still forming.

When a market hinges on an unproven regulatory path, the first mover's real asset is the permission loop: the landing and licensing track record every future competitor must also build.

As of September 2026, Varda has returned multiple W-series capsules to Earth and launched W-4 under the FAA's first reentry-vehicle operator license, with an in-house satellite bus and heatshield replacing the original Rocket Lab hardware. The $187M Series C funds a 10,000 sq ft crystallization laboratory in El Segundo and a faster mission cadence, plus an office in Huntsville, Alabama. Revenue so far comes mainly from government reentry-testing partners such as AFRL and NASA. The core bet — that pharmaceutical companies will pay for in-space processing — is still unproven commercially.